Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.

Haas, David W; Acosta, Edward P

Haas, David W; Acosta, Edward P.

Affiliation

Haas DW; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Acosta EP; Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA.

Clin Infect Dis ; 72(10): 1820-1822, 2021 05 18.

Article in En | MEDLINE | ID: mdl-32667979

Subject(s)

Anti-HIV Agents; HIV Infections; Alkynes; Anti-HIV Agents/therapeutic use; Benzoxazines/therapeutic use; Cyclopropanes/therapeutic use; Cytochrome P-450 CYP2B6/genetics; HIV Infections/drug therapy; Heterocyclic Compounds, 3-Ring; Humans; Oxazines; Pharmacogenetics; Piperazines; Pyridones

Key words

dolutegravir; efavirenz; pharmacogenetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Limits: Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Limits: Humans Language: En Year: 2021 Type: Article